T. Iveson

Capecitabine and oxaliplatin for advanced esophagogastric cancer (2008)

Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., ...

Background: We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced...

The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer - A phase II study (2006)

Michels, J., Geldart, T., Darby, A., Craddock, L., Iveson, A., Richardson, L., ...

Aims To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer. Materials and methods A phase II study. Results In...

An unusual differential diagnosis of penile warts: metastases from rectal carcinoma (2006)

Cathomas, R., Geldart, T.R., Iveson, T., Singh, N., Rowen, D.

Patients with penile lesions, such as virally induced papillomata, frequently present to genitourinary medicine clinics and general practitioners. Their diagnosis is usually based on clinical...

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials (2006)

Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., ...

The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above ( >= 70) in comparison to younger patients. 1080 patients were...

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials (2006)

Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., ...

The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (70) in comparison to younger patients. 1080 patients were...

Management of advanced colorectal cancer: state of the art (2006)

Saunders, M., Iveson, T.

Colorectal cancer ( CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and...

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer (2005)

Chau, I., Norman, A.R., Cunningham, D., Tait, D., Ross, P.J., Iveson, T., ...

Background: We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly...

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF (2005)

Sumpter, K., Harper-Wynne, C., Cunningham, D., Rao, S., Tebbutt, N., Norman, A.R., ...

The purpose of the study was to establish the optimal dose of capecitabine (X) to be used within a multicentre, randomised study evaluating the potential roles of oxaliplatin (O) and X in chemonaive...

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer (2004)

Rao, S., Cunningham, D., De Gramont, A., Scheithauer, W., Smakal, M., Humblet, Y., ...

Purpose: To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer (CRC) in a multicenter, double-blind, prospective randomized study. Patients and...

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer (2003)

Saini, A., Norman, A.R., Cunningham, D., Chau, I., Hill, M., Tait, D., ...

We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard...

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary (2003)

Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., ...

No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C...

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer (2002)

Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., ...

Purpose: We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) (ECF) with the...

A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer (2002)

Tebbutt, N.C., Norman, A., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., ...

Background: this randomised study compared protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin C (MMC) in patients with advanced oesophago-gastric cancer. Patients and...

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer (2001)

Clarke-Pearson, D.L., Van Le, L., Iveson, T., Whitney, C.W., Hanjani, P., Kristensen, G., ...

Purpose: To evaluate oral topotecan as single-agent, second-line therapy in patients with ovarian cancer previously treated with a platinum-based regimen. Patients and Methods: Patients (N = 116)...

More oncologists, please.

Johnston, S., Iveson, T.